Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 293

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A Randomized, Double-Blind Placebo Controlled Trial of Balapiravir, a Polymerase Inhibitor, in Adult Dengue Patients

Open access
Nguyen, Nguyet Minh, Tran, Chau Nguyen Bich, Phung, Lam Khanh, Duong, Kien Thi Hue, Huynh, Huy le Anh, Farrar, Jeremy, Nguyen, Quyen Than Ha, Tran, Hien Tinh, Nguyen, Chau Van Vinh, Merson, Laura, Hoang, Long Truong, Hibberd, Martin L., Aw, Pauline P. K., Wilm, Andreas, Nagarajan, Niranjan, Nguyen, Dung Thi, Pham, Mai Phuong, Nguyen, Truong Thanh, Javanbakht, Hassan, Klumpp, Klaus, Hammond, Janet, Petric, Rosemary, Wolbers, Marcel, Nguyen, Chinh Tran, Simmons, Cameron P.·2013·The Journal of Infectious Diseases

Abstract

BACKGROUND: Dengue is the most common arboviral infection of humans. There are currently no specific treatments for dengue. Balapiravir is a prodrug of a nucleoside analogue (called R1479) and an inhibitor of hepatitis C virus replication in vivo. METHODS: We conducted in vitro experiments to determine the potency of balapiravir against dengue viruses and then an exploratory, dose-escalating, randomized placebo-controlled trial in adult male patients with dengue with <48 hours of fever. RESULTS: The clinical and laboratory adverse event profile in patients receiving balapiravir at doses of 1500 mg (n = 10) or 3000 mg (n = 22) orally for 5 days was similar to that of patients receiving placebo (n = 32), indicating balapiravir was well tolerated. However, twice daily assessment of viremia and daily assessment of NS1 antigenemia indicated balapiravir did not measurably alter the kinetics of these virological markers, nor did it reduce the fever clearance time. The kinetics of plasma cytokine concentrations and the whole blood transcriptional profile were also not attenuated by balapiravir treatment. CONCLUSIONS: Although this trial, the first of its kind in dengue, does not support balapiravir as a candidate drug, it does establish a framework for antiviral treatment trials in dengue and provides the field with a clinically evaluated benchmark molecule. CLINICAL TRIALS REGISTRATION: NCT01096576.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/infdis/jis470

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 293

Metadata

Authors
Nguyen, N. M., Tran, C. N. B., Phung, L. K., Duong, K. T. H., Huynh, H. L. A., Farrar, J., Nguyen, Q. T. H., Tran, H. T., Nguyen, C. V. V., Merson, L., Hoang, L. T., Hibberd, M. L., Aw, P. P. K., Wilm, A., Nagarajan, N., Nguyen, D. T., Pham, M. P., Nguyen, T. T., Javanbakht, H., Klumpp, K., Hammond, J., Petric, R., Wolbers, M., Nguyen, C. T., & Simmons, C. P.
Venue
The Journal of Infectious Diseases
Published
2012-07-17
Volume
207
Issue
9
Pages
1442-1450
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W2103800735
Cited by
293
References
2
FWCI
15.63
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Randomized, Double-Blind Placebo Controlled Trial of Balapiravir, a Polymerase Inhibitor, in Adult Dengue Patients. https://app.cochat.ai/papers/10.1093/infdis/jis470
The paper
Nguyen, N. M., Tran, C. N. B., Phung, L. K., Duong, K. T. H., Huynh, H. L. A., Farrar, J., Nguyen, Q. T. H., Tran, H. T., Nguyen, C. V. V., Merson, L., Hoang, L. T., Hibberd, M. L., Aw, P. P. K., Wilm, A., Nagarajan, N., Nguyen, D. T., Pham, M. P., Nguyen, T. T., Javanbakht, H., . . . Simmons, C. P. (2013). A Randomized, Double-Blind Placebo Controlled Trial of Balapiravir, a Polymerase Inhibitor, in Adult Dengue Patients. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jis470

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.